Markets:

Overview

News

Currencies

International

Treasuries

Repligen Corporation - Common Stock (NQ:RGEN)

123.00 -3.55 (-2.81%)

Streaming Delayed Price Updated: 12:46 PM EDT, Jun 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Repligen Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Drug Development Inputs & Services Stocks Q2 Results: Benchmarking Repligen (NASDAQ:RGEN)

September 22, 2025

Wrapping up Q2 earnings, we look at the numbers and key takeaways for the drug development inputs & services stocks, including Repligen (NASDAQ:RGEN) and its peers.

Via StockStory

This Sarepta Therapeutics Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday ↗

September 22, 2025

Via Benzinga

Small-Cap and Value Stocks Stage a Powerful Comeback: A Market Rebalancing Act Underway

September 19, 2025

After years of being overshadowed by their large-cap growth counterparts, small-cap and value stocks are experiencing a significant resurgence, signaling a potential seismic shift in market leadership....

Via MarketMinute

Analyst Expectations For Repligen's Future ↗

September 03, 2025

Via Benzinga

Earnings Scheduled For July 29, 2025 ↗

July 29, 2025

Via Benzinga

Repligen (RGEN) Stock Is Up, What You Need To Know

September 16, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 4.4% in the afternoon session after investment firm Stifel reiterated its Buy rating and maintained a $207.00 price...

Via StockStory

Anchored at 4%: Why the Steady 10-Year Treasury Yield is Key to Unlocking the Fed's Stimulus Power

September 15, 2025

The U.S. financial markets are currently at a critical juncture, with the stability of the 10-year Treasury yield hovering steadfastly around the 4% mark. This apparent calm in long-term borrowing...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

1 Cash-Producing Stock with Exciting Potential and 2 We Avoid

September 13, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

Why Repligen (RGEN) Stock Is Down Today

September 12, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.5% in the afternoon session after Jefferies lowered its price target on the stock.

Via StockStory

Topics Artificial Intelligence Economy

Bond Yields Tumble as Investors Brace for Aggressive Fed Rate Cuts

September 08, 2025

U.S. Treasury yields have recently experienced a significant decline, with the benchmark 10-year Treasury note falling to its lowest levels since April 2025. This sharp dip in yields reflects a...

Via MarketMinute

Topics Bonds Economy Supply Chain

3 Cash-Heavy Stocks We Find Risky

September 08, 2025

A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.

Via StockStory

Repligen, Revvity, Avantor, Fortrea, and Azenta Shares Skyrocket, What You Need To Know

August 22, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded, as Fed Chair Jerome Powell delivered dovish remarks at the much-awaited Jackson Hole symposium. Powell suggested...

Via StockStory

Topics Economy

3 of Wall Street’s Favorite Stocks with Warning Signs

August 22, 2025

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...

Via StockStory

3 Unprofitable Stocks We Steer Clear Of

August 21, 2025

Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth.

Via StockStory

3 Cash-Producing Stocks We Think Twice About

August 18, 2025

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.

Via StockStory

NeoGenomics, Progyny, Repligen, Revvity, and Waters Corporation Shares Are Soaring, What You Need To Know

August 13, 2025

A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer...

Via StockStory

Topics Economy

AMN Healthcare Services, NeoGenomics, Acadia Healthcare, BrightSpring Health Services, and Repligen Shares Are Soaring, What You Need To Know

August 12, 2025

A number of stocks jumped in the afternoon session after positive inflation data fueled hopes for an interest rate cut by the Federal Reserve. The latest Consumer Price Index (CPI) report showed...

Via StockStory

Topics Bonds Economy Stocks

RGEN Q2 Deep Dive: Chromatography and Filtration Drive Growth, Guidance Lifted Amid New Modalities Uncertainty

August 12, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q2 CY2025, with sales up 14.8% year on year to $182.4 million. The company’s full-year...

Via StockStory

1 Safe-and-Steady Stock on Our Buy List and 2 We Turn Down

August 07, 2025

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere.

Via StockStory

Repligen Stock Outlook: Risk Skewed To The Downside Through 2026 ↗

July 31, 2025

Repligen stock has been in a prolonged downtrend, and Adhishthana principles suggest more weakness ahead. Here's what investors should track...

Via Benzinga

Why Repligen (RGEN) Stock Is Up Today

July 29, 2025

Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 7.8% in the morning session after the company reported strong second-quarter 2025 financial results and raised its...

Via StockStory

Topics Artificial Intelligence Lawsuit

Repligen Corp (NASDAQ:RGEN) Q2 2025 Earnings: Revenue Beat Offsets EPS Miss as Stock Rises in Pre-Market ↗

July 29, 2025

Repligen Corp's Q2 2025 earnings show revenue beat estimates at $182.4M, but EPS missed at $0.37. Stock rose 2.65% pre-market amid strong order growth.

Via Chartmill

Repligen’s (NASDAQ:RGEN) Q2 Sales Top Estimates, Full-Year Sales Guidance is Optimistic

July 29, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) reported Q2 CY2025 results beating Wall Street’s revenue expectations, with sales up 14.8% year on year to $182.4 million. The...

Via StockStory

Repligen (RGEN) Reports Q2: Everything You Need To Know Ahead Of Earnings

July 27, 2025

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting earnings this Tuesday before the bell. Here’s what to look for.

Via StockStory

Forecasting The Future: 6 Analyst Projections For Repligen ↗

July 22, 2025

Via Benzinga

Repligen, Bruker, Fortrea, Azenta, and Biogen Stocks Trade Down, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit

1 Healthcare Stock to Target This Week and 2 to Be Wary Of

July 03, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

What Analysts Are Saying About Repligen Stock ↗

June 24, 2025

Via Benzinga

Sarepta Therapeutics, KULR Technology Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 16, 2025

Via Benzinga

1 Unprofitable Stock for Long-Term Investors and 2 to Ignore

June 10, 2025

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.

Via StockStory

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.